Aravive (ARAV) Competitors $0.04 0.00 (0.00%) As of 04/25/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsSustainabilityTrendsBuy This Stock ARAV vs. NERV, TXMD, BGXX, AFMD, RLYB, RLMD, PHXM, IXHL, GOVX, and NXTCShould you be buying Aravive stock or one of its competitors? The main competitors of Aravive include Minerva Neurosciences (NERV), TherapeuticsMD (TXMD), Bright Green (BGXX), Affimed (AFMD), Rallybio (RLYB), Relmada Therapeutics (RLMD), PHAXIAM Therapeutics (PHXM), Incannex Healthcare (IXHL), GeoVax Labs (GOVX), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry. Aravive vs. Minerva Neurosciences TherapeuticsMD Bright Green Affimed Rallybio Relmada Therapeutics PHAXIAM Therapeutics Incannex Healthcare GeoVax Labs NextCure Minerva Neurosciences (NASDAQ:NERV) and Aravive (NASDAQ:ARAV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Is NERV or ARAV more profitable? Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% Aravive N/A N/A N/A Does the media refer more to NERV or ARAV? In the previous week, Minerva Neurosciences had 4 more articles in the media than Aravive. MarketBeat recorded 4 mentions for Minerva Neurosciences and 0 mentions for Aravive. Minerva Neurosciences' average media sentiment score of 0.22 beat Aravive's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Minerva Neurosciences Neutral Aravive Neutral Which has better earnings and valuation, NERV or ARAV? Minerva Neurosciences has higher earnings, but lower revenue than Aravive. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M$0.199.37Aravive$6.99M0.42-$76.32MN/AN/A Do analysts prefer NERV or ARAV? Minerva Neurosciences presently has a consensus price target of $5.00, suggesting a potential upside of 180.90%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Minerva Neurosciences is more favorable than Aravive.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, NERV or ARAV? Minerva Neurosciences has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Aravive has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500. Does the MarketBeat Community prefer NERV or ARAV? Minerva Neurosciences received 243 more outperform votes than Aravive when rated by MarketBeat users. However, 62.28% of users gave Aravive an outperform vote while only 55.88% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34755.88% Underperform Votes27444.12% AraviveOutperform Votes10462.28% Underperform Votes6337.72% Do institutionals and insiders hold more shares of NERV or ARAV? 34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 8.6% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryMinerva Neurosciences and Aravive tied by winning 6 of the 12 factors compared between the two stocks. Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAV vs. The Competition Export to ExcelMetricAravivePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95M$6.71B$5.47B$7.82BDividend YieldN/A3.17%5.43%4.29%P/E RatioN/A7.2322.3918.43Price / Sales0.42239.71391.41101.46Price / CashN/A65.8538.1834.62Price / BookN/A6.306.684.19Net Income-$76.32M$143.17M$3.22B$248.05M7 Day PerformanceN/A8.00%6.25%6.53%1 Month PerformanceN/A-4.16%-2.81%-2.16%1 Year PerformanceN/A-2.78%16.47%4.71% Aravive Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading VolumeNERVMinerva Neurosciences3.5714 of 5 stars$1.66+3.8%$5.00+201.2%-27.3%$11.61MN/A-3.779Upcoming EarningsNegative NewsTXMDTherapeuticsMD1.3346 of 5 stars$1.00-1.4%N/A-38.5%$11.53M$1.76M0.00420Analyst ForecastGap DownBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownAFMDAffimed3.4635 of 5 stars$0.70-4.0%$13.50+1,818.2%-80.8%$11.33M$877,000.000.00200Analyst ForecastRLYBRallybio2.4993 of 5 stars$0.27+6.0%$10.00+3,672.2%-81.6%$11.03M$636,000.00-0.1740Positive NewsGap UpRLMDRelmada Therapeutics4.2972 of 5 stars$0.32+11.5%$4.25+1,215.8%-82.6%$10.72MN/A-0.1110PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049News CoverageIXHLIncannex Healthcare0.9252 of 5 stars$0.59-1.7%N/A-74.7%$10.54M$98,000.00-0.423Short Interest ↑Positive NewsGap DownGOVXGeoVax Labs2.5007 of 5 stars$0.76-8.4%$12.90+1,597.1%-33.6%$10.52M$3.95M-0.1310News CoverageGap UpNXTCNextCure4.6615 of 5 stars$0.37+2.2%$3.50+848.5%-64.3%$10.35MN/A-0.1890Upcoming EarningsShort Interest ↓Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies NERV Competitors TXMD Competitors BGXX Competitors AFMD Competitors RLYB Competitors RLMD Competitors PHXM Competitors IXHL Competitors GOVX Competitors NXTC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARAV) was last updated on 4/26/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARAV Stock Free ARAV Stock Alerts